Burris Receives $740,000 Grant from Mallinckrodt Pharmaceuticals
Published on 14 February 2020
Tom Burris, Ph.D., FAAAS, FAHA, Alumni Chair in Pharmaceutical Education and vice president for research at St. Louis College of Pharmacy, recently received grant funds totaling more than $740,000 from Mallinckrodt Pharmaceuticals.
The funding will support Burris’s research in the Center for Clinical Pharmacology to develop drugs targeting muscle function. Specifically, the research will focus on the creation of therapeutics to treat Duchenne muscular dystrophy and muscle loss caused by aging, known as sarcopenia.
Burris will serve as the principal investigator on the project, and will be supported by Bahaa El-Gendy, Ph.D., assistant professor of medicinal chemistry at the College, who will serve as the co-principal investigator.
“As we continue our work to examine drug compounds that have the potential to improve muscle function and accelerate muscle regeneration, this funding from Mallinckrodt will be very important,” Burris said. “We’re grateful for this grant, and we look forward to utilizing this funding to conduct research that we hope will result in the creation of drugs that will ultimately positively impact the health and quality of life of those suffering from musculoskeletal disorders.”
This research award from Mallinkrodt and other recent grant awards are evidence of the College’s growing capacity and recognition as a research institution. Across the College, faculty researchers are engaged in exciting projects, both in individual laboratories and through the College’s academic and research centers.
To learn more about this project and the wide range of research currently underway at the Center for Clinical Pharmacology, visit clinicalpharmstl.org. To learn more about research at the College, visit stlcop.edu/research.
Explore more stories in the category of: Research